BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 8
• 9
• 10
• 11
• 12
• 13
• 15
• 16
• 17
• 18
• 19
• 22
• 23
• 24
• 25
• 26
• 29
• 30
• 31

• KFSHRC Performs Over 5,000 Successful Kidney Transplants

  King Faisal Specialist Hospital and Research Centre has successfully performed 5,000 kidney transplants since the inception of its Transplant Program in 1981, placing it among a select group of leading global health centres that have achieved this milestone.

  July 1, 2024

   · 

  2 min read
• Press Releases

  Avid Bioservices to Report Financial Results for Quarter and Fiscal Year Ended April 30, 2024, After Market Close on July 2, 2024

  Avid Bioservices, Inc. today announced that it will report financial results for the quarter and fiscal year ended April 30, 2024, on July 2, 2024, after market close and will host a webcast at 1:30 PM Pacific Time (4:30 PM Eastern Time).

  July 1, 2024

   · 

  1 min read
• Press Releases

  Q32 Bio Joins Russell 3000® Index

  Q32 Bio Inc. today announced that the company is joining the broad-market Russell 3000 ® Index at the conclusion of the 2024 Russell Indexes annual reconstitution, effective upon the U.S. market opening today, July 1, 2024.

  July 1, 2024

   · 

  6 min read
• Business

  Labcorp to Announce Second Quarter Financial Results on August 1, 2024

  Labcorp will release its financial results for the second quarter of 2024 before the market opens on Thursday, August 1, 2024.

  July 1, 2024

   · 

  1 min read
• Drug Development

  Recce Pharmaceuticals Reports Positive Data from Phase I/II Urinary Tract Infection (UTI) / Urosepsis Rapid Infusion Trial of RECCE® 327

  Recce Pharmaceuticals Ltd today announced positive data from a Phase I/II trial for urinary tract infections (UTIs) and urosepsis, demonstrating that its lead candidate, RECCE® 327 (R327), administered intravenously is safe and efficacious against Escherichia coli (E. coli).

  July 1, 2024

   · 

  5 min read
• Pharm Country

  Amneal Expands Biosimilars Portfolio to Eight Products with Addition of Omalizumab Biosimilar

  Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”) today announced the addition of omalizumab, referencing XOLAIR ® , to its biosimilar pipeline.

  July 1, 2024

   · 

  7 min read
• Press Releases

  KaliVir Immunotherapeutics Announces FDA Clearance of Investigational New Drug (IND) for Oncolytic Immunotherapy VET3-TGI for Solid Tumors

  KaliVir Immunotherapeutics, Inc. today announced that the FDA has cleared the Investigational New Drug (IND) application for the STEALTH-001 study of VET3-TGI in patients with incurable, advanced solid tumors.

  July 1, 2024

   · 

  2 min read
• Press Releases

  Kashiv BioSciences Enters into Exclusive Licensing Agreement with Amneal for Commercialization of a Proposed Biosimilar to XOLAIR® (Omalizumab)

  Kashiv BioSciences, LLC (“Kashiv” or the “Company”) today announced that it has entered into an exclusive licensing agreement for ADL018 with Amneal Pharmaceuticals, Inc.

  July 1, 2024

   · 

  7 min read
• Defence’s AccuTOX Boosts and Synergizes with Immune Checkpoint Inhibitors

  Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) (“Defence” or the “Company”), a Canadian biopharmaceutical company developing novel immune-oncology vaccines and drug delivery technologies, is please to announce that Defence’s Accum-002TM (“AccuTOX®") has different mode

  July 1, 2024

   · 

  5 min read
• Protect Pharmaceutical Corp. Issues Corporate Update

  Protect Pharmaceutical Corp.'s (OTC: PRTT) (“Company”) President, Ali Yildiz, provides its shareholders with the following informational update: “July 1, 2024 Dear Shareholders: The Company’s PCAOB audit for the fiscal year of 2023 is near completion.

  July 1, 2024

   · 

  4 min read